Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Affimed stock logo
AFMD
Affimed
$0.18
-34.9%
$0.25
$0.07
$5.84
$2.92M2.074.70 million shs22.99 million shs
Homology Medicines, Inc. stock logo
FIXX
Homology Medicines
$1.18
$0.46
$17.51
$978.01M-0.1390,307 shs22,300 shs
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
$0.61
-9.0%
$0.61
$0.24
$4.37
$22.24M0.59970,833 shs88,211 shs
Spectrum Pharmaceuticals, Inc. stock logo
SPPI
Spectrum Pharmaceuticals
$1.03
$1.01
$0.32
$1.57
$211.41M2.151.93 million shsN/A
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
$32.21
-2.3%
$31.88
$26.74
$46.00
$2.53B1.1638,352 shs595,207 shs
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Affimed stock logo
AFMD
Affimed
0.00%0.00%0.00%-70.82%-96.41%
Homology Medicines, Inc. stock logo
FIXX
Homology Medicines
0.00%0.00%0.00%0.00%0.00%
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
-8.97%-2.71%-20.42%+106.43%-85.68%
Spectrum Pharmaceuticals, Inc. stock logo
SPPI
Spectrum Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
-2.33%-7.19%-0.15%+2.58%-18.56%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Affimed stock logo
AFMD
Affimed
2.862 of 5 stars
4.00.00.04.30.60.01.3
Homology Medicines, Inc. stock logo
FIXX
Homology Medicines
0.6637 of 5 stars
0.00.00.04.80.60.80.6
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
4.7702 of 5 stars
3.15.00.04.41.84.21.3
Spectrum Pharmaceuticals, Inc. stock logo
SPPI
Spectrum Pharmaceuticals
0.4484 of 5 stars
0.00.00.04.70.60.00.6
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
3.4626 of 5 stars
4.54.00.00.01.62.50.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Affimed stock logo
AFMD
Affimed
2.00
Hold$3.621,895.87% Upside
Homology Medicines, Inc. stock logo
FIXX
Homology Medicines
0.00
N/AN/AN/A
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
2.25
Hold$5.00719.67% Upside
Spectrum Pharmaceuticals, Inc. stock logo
SPPI
Spectrum Pharmaceuticals
0.00
N/AN/AN/A
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
3.00
Buy$54.8270.19% Upside

Current Analyst Ratings Breakdown

Latest RLMD, SPPI, XENE, FIXX, and AFMD Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/14/2025
Affimed stock logo
AFMD
Affimed
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
5/14/2025
Affimed stock logo
AFMD
Affimed
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral
5/14/2025
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$55.00
5/13/2025
Affimed stock logo
AFMD
Affimed
Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
5/13/2025
Affimed stock logo
AFMD
Affimed
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Equal Weight$11.00 ➝ $0.10
5/13/2025
Affimed stock logo
AFMD
Affimed
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Market Perform$5.00 ➝ $0.39
5/13/2025
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$50.00 ➝ $47.00
5/13/2025
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$58.00 ➝ $55.00
5/13/2025
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$53.00 ➝ $53.00
5/13/2025
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$55.00 ➝ $55.00
5/13/2025
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$60.00 ➝ $55.00
(Data available from 7/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Affimed stock logo
AFMD
Affimed
$877K3.33N/AN/A$4.19 per share0.04
Homology Medicines, Inc. stock logo
FIXX
Homology Medicines
$1.16M0.00N/AN/A$1.26 per share0.00
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
N/AN/AN/AN/A$1.18 per shareN/A
Spectrum Pharmaceuticals, Inc. stock logo
SPPI
Spectrum Pharmaceuticals
$10.11M20.91N/AN/A$0.15 per share6.87
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
$9.43M262.09N/AN/A$9.90 per share3.25
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Affimed stock logo
AFMD
Affimed
-$114.66MN/A0.00N/AN/A-7,836.26%-193.84%-107.24%9/1/2025 (Estimated)
Homology Medicines, Inc. stock logo
FIXX
Homology Medicines
-$112.96M-$1.96N/AN/AN/A-4,779.31%-102.52%-74.91%N/A
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
-$79.98M-$2.51N/AN/AN/AN/A-181.26%-151.23%8/6/2025 (Estimated)
Spectrum Pharmaceuticals, Inc. stock logo
SPPI
Spectrum Pharmaceuticals
-$75.40M-$0.36N/A14.71N/AN/A-218.44%-66.16%N/A
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
-$234.33M-$3.23N/AN/AN/AN/A-32.44%-30.84%8/14/2025 (Estimated)

Latest RLMD, SPPI, XENE, FIXX, and AFMD Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2025Q2 2025
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
-$0.25N/AN/AN/AN/AN/A
5/12/2025Q1 2025
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
-$0.31-$0.58-$0.27-$0.58N/AN/A
5/12/2025Q1 2025
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
-$0.90-$0.83+$0.07-$0.83$1.64 million$7.50 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Affimed stock logo
AFMD
Affimed
N/AN/AN/AN/AN/A
Homology Medicines, Inc. stock logo
FIXX
Homology Medicines
N/AN/AN/AN/AN/A
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
N/AN/AN/AN/AN/A
Spectrum Pharmaceuticals, Inc. stock logo
SPPI
Spectrum Pharmaceuticals
N/AN/AN/AN/AN/A
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Affimed stock logo
AFMD
Affimed
0.13
1.93
1.93
Homology Medicines, Inc. stock logo
FIXX
Homology Medicines
N/A
7.25
7.25
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
N/A
5.29
5.29
Spectrum Pharmaceuticals, Inc. stock logo
SPPI
Spectrum Pharmaceuticals
N/A
2.71
2.38
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
N/A
17.66
17.66

Institutional Ownership

CompanyInstitutional Ownership
Affimed stock logo
AFMD
Affimed
30.82%
Homology Medicines, Inc. stock logo
FIXX
Homology Medicines
31.32%
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
45.24%
Spectrum Pharmaceuticals, Inc. stock logo
SPPI
Spectrum Pharmaceuticals
21.67%
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
95.45%
CompanyEmployeesShares OutstandingFree FloatOptionable
Affimed stock logo
AFMD
Affimed
20016.10 million15.49 millionOptionable
Homology Medicines, Inc. stock logo
FIXX
Homology Medicines
758.13 million48.77 millionOptionable
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
1033.19 million26.32 millionOptionable
Spectrum Pharmaceuticals, Inc. stock logo
SPPI
Spectrum Pharmaceuticals
86205.25 million199.70 millionOptionable
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
21076.73 million72.50 millionOptionable

Recent News About These Companies

Xenon Appoints CEO Ian Mortimer as Interim CFO
Xenon Joins the Russell 3000® and Russell 2000® Indexes

New MarketBeat Followers Over Time

Media Sentiment Over Time

Affimed stock logo

Affimed NASDAQ:AFMD

$0.18 -0.10 (-34.95%)
As of 05/19/2025

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company's lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid. It develops AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. It has collaboration with Artiva Biotherapeutics to develop the combination of acimtamig and AlloNK; license and strategic collaboration agreement with Roivant Sciences Ltd. to develop and commercialize novel ICE molecules, including AFM32, in oncology; and strategic collaboration agreement with Genentech for the development of certain product candidates, which includes novel NK cell engager-based immunotherapeutics to treat multiple cancers. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Mannheim, Germany.

Homology Medicines stock logo

Homology Medicines NASDAQ:FIXX

Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases in the United States. The company offers proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a nuclease-free gene editing mobility, gene therapy or for various genetic disorders. Its earlier stage product candidates comprising HMI-202, an investigational gene therapy which completed IND-enabling studies for the treatment of metachromatic leukodystrophy; and HMI-104 which completed IND-enabling studies. Homology Medicines, Inc. was incorporated in 2015 and is headquartered in Bedford, Massachusetts.

Relmada Therapeutics stock logo

Relmada Therapeutics NASDAQ:RLMD

$0.61 -0.06 (-8.97%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$0.61 +0.00 (+0.16%)
As of 07/11/2025 07:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida.

Spectrum Pharmaceuticals stock logo

Spectrum Pharmaceuticals NASDAQ:SPPI

Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products. It offers ROLVEDON(Eflapegrastim), a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia. The company develops Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology license agreement with The University of Texas M.D. Anderson Cancer Center; and license agreement with Therapyx, Inc. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Boston, Massachusetts.

Xenon Pharmaceuticals stock logo

Xenon Pharmaceuticals NASDAQ:XENE

$32.21 -0.77 (-2.33%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$32.17 -0.04 (-0.11%)
As of 07/11/2025 05:23 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.